Cocrystal Pharma, Inc. — Form SCHEDULE 13D/A
Filed August 7, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
This is an amended Schedule 13D/A filing by Phillip Frost MD and associates regarding Cocrystal Pharma, Inc., filed August 7, 2026. The filing itself contains no substantive disclosures of share counts, purchase prices, dates of transactions, or changes in beneficial ownership in the provided text excerpt. The amendment appears to be a procedural filing updating prior disclosure, but specific details of what changed are not present in this header/metadata section.
Why this rating
No material transaction, ownership change, or business event disclosed in text. Routine SEC procedural amendment; significance cannot be assessed without actual substantive content.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.